Search details
1.
CDK4/6 inhibition triggers anti-tumour immunity.
Nature
; 548(7668): 471-475, 2017 08 24.
Article
in English
| MEDLINE | ID: mdl-28813415
2.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33460574
3.
Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Oncologist
; 24(8): 1041-1047, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30578311
4.
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Oncologist
; 24(7): e441-e449, 2019 07.
Article
in English
| MEDLINE | ID: mdl-30518616
5.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 497-509, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29501363
6.
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.
Breast Cancer Res Treat
; 157(3): 587-96, 2016 06.
Article
in English
| MEDLINE | ID: mdl-27271765
7.
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.
Breast Cancer Res Treat
; 155(1): 127-32, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26708471
8.
Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast.
Ann Surg Oncol
; 22(13): 4280-6, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-25893416
9.
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Lancet Oncol
; 14(3): 244-8, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23414588
10.
Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial.
J Am Coll Surg
; 238(3): 303-311, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-38047578
11.
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
J Clin Invest
; 134(7)2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-38300710
12.
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
Oncologist
; 18(2): 134-40, 2013.
Article
in English
| MEDLINE | ID: mdl-23359433
13.
Targeted therapies in breast cancer: are heart and vessels also being targeted?
Breast Cancer Res
; 14(3): 209, 2012 Jun 19.
Article
in English
| MEDLINE | ID: mdl-22713170
14.
Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).
Breast Cancer Res Treat
; 133(1): 387-91, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22367645
15.
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
Invest New Drugs
; 30(6): 2433-42, 2012 Dec.
Article
in English
| MEDLINE | ID: mdl-22415797
16.
The natural history of hormone receptor-positive breast cancer.
Oncology (Williston Park)
; 26(8): 688-94, 696, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22957400
17.
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
NAR Cancer
; 4(2): zcac018, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35734391
18.
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Cancer Res
; 82(20): 3673-3686, 2022 10 17.
Article
in English
| MEDLINE | ID: mdl-35950920
19.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
J Clin Oncol
; 40(5): 449-458, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-34995105
20.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
J Clin Oncol
; 40(3): 282-293, 2022 01 20.
Article
in English
| MEDLINE | ID: mdl-34874182